Skip to content

Serum Chordecone Concentration in Guadeloupean Population: Impact of a Multidisciplinary Support Program on the Reduction of the Contamination Level.

Serum Chordecone Concentration in Guadeloupean Population: Impact of a Multidisciplinary Support Program on the Reduction of the Contamination Level.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07251036
Acronym
ChlorGua
Enrollment
3000
Registered
2025-11-26
Start date
2022-06-26
Completion date
2028-06-30
Last updated
2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chlordecone Level

Keywords

risk factors, pesticides, Guadeloupe, chlordecone

Brief summary

The French West Indies (Guadeloupe, Martinique) are characterized by a major use of pesticides in bananas plantation from the 1950s. These crops used organochlorine insecticides and especially chlordecone (CLD) from 1972 to 1993. The lack of biotic and abiotic degradation of CLD led to persistent soil pollution, contamination of surface and deep waters, of numerous plant and animal, and of the population. The extent and persistence of CLD contamination over time is a major issue for these territories. An internal reference value (0.4μg/l) was recently determined. Although useful for a population approach, it must be used with caution for the interpretation of an individual result. In response to the strong social demand expressed by the population for access to free chlordecone blood tests, a screening program for blood chlordecone test was authorized by the 2019 French Finance Act.

Detailed description

The target populations will receive an invitation letter with an information notice and a consent form. The referral physician will explain the program and the research project and prescribe a standardized blood sample test. Blood samples will be taken in one of the biology laboratories participating in the project. Serum chordecone test will be performed by the Pasteur Institute of Guadeloupe. Blood samples for biological collection will be sent to the Biological Resource Center, Karubiotec™. The result of the chlordécone level will be sent back to each subject with a recommendation note based on the chlordécone level value. Phone contact information for those who consented to the study will be forwarded to the research assistant for the questionnaire.

Interventions

OTHERCHLORGUA

The target populations will receive an invitation letter with an information notice and a consent form. The referral physician will explain the program and the research project and prescribe a standardized blood sample test. Blood samples will be taken in one of the biology laboratories participating in the project. Serum chordecone test will be performed by the Pasteur Institute of Guadeloupe. Blood samples for biological collection will be sent to the Biological Resource Center, Karubiotec™. The result of the chlordécone level will be sent back to each subject with a recommendation note based on the chlordécone level value. Phone contact information for

Sponsors

Centre Hospitalier Universitaire de la Guadeloupe
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All subject overs 18 years of age residing in Guadeloupe invited to participate to the program by the Regional Health Agency or subjects who requested a test from their doctor in the framework of the ministerial measure. * Subjects who have read the information note and signed the consent to participate in the study * Subjects with social security coverage

Exclusion criteria

* Refusal to participate * Person not affiliated with a social security scheme * Person under legal protection (safeguard of justice, guardianship, curatorship, etc.

Design outcomes

Primary

MeasureTime frameDescription
chlordecone levelbetween Day0 to Day15ug/l
risk factorsbetween day 15 and day 45 ,chlordeconemia survey

Secondary

MeasureTime frameDescription
chlordecone levelAt 9 months after interventionug/l
impact of an interventionbetween day 15 to day 45, at month 9 and month 18chlordeconemia survey

Countries

Guadeloupe

Contacts

Primary ContactValérie HAMONY-SOTER
valerie.soter@chu-guadeloupe.fr+590590934686
Backup ContactEunice NUBRET
eunice.nubret@chu-guadeloupe.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026